Kailera Therapeutics, Inc. (KLRA) Stock Price & Analysis
Kailera Therapeutics, Inc. (KLRA) closed at USD 13.27 on Thursday, October 22, 2026, up 2.71% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 12.92; the Oct 22, 2026 session ranged USD 12.56–13.34 on volume of 855,470 shares. Market capitalization is $1.72B, with a 52-week range of USD 9.76–28.23 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/KLRA.md
Key facts (KLRA)
- Insider open-market purchases, last ~7 months: 5 Form 4 filings, $327M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.83 on a 1–5 scale) (6 analysts), mean target USD 42.4 (range 30–57).
- Total return with dividends: 1Y -49.0% vs S&P 500 +14.9%; 5Y -49.0% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD -1.01, revenue estimate $0K.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (KLRA)
P/B 1.5x · Earnings yield -13.78%
Insider purchases (SEC Form 4, open-market, last ~7 months) (KLRA)
5 purchases, $327M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-04-20 | Rtw Investments, Lp | 500,000 | $8.0M | 16 | Too little history (no open-market trades in 2023–2025) | |
| 2026-04-20 | Bain Capital Investors Llc | 8,398,438 | $134M | 16 | Too little history (no open-market trades in 2023–2025) | |
| 2026-04-20 | Koppel Adam | Director | 1,562,500 | $25.0M | 16 | Too little history (no open-market trades in 2023–2025) |
| 2026-04-20 | Bain Capital Life Sciences Investors, Llc | 1,562,500 | $25.0M | 16 | Too little history (no open-market trades in 2023–2025) | |
| 2026-04-20 | Kaplan Andrew T. | Director | 8,398,438 | $134M | 16 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (KLRA)
Consensus Buy (mean 1.83 on a 1–5 scale), 6 analysts; mean target USD 42.4 (low 30, high 57).
Total return (dividends reinvested) (KLRA)
| 1Y (from 2026-04-17) | 5Y (from 2026-04-13) | |
|---|---|---|
| Total return | -49.0% | -49.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | — | — |
| Volatility (annualized) | 73.3% | 64.7% |
| Max drawdown | -61.5% (Apr 2026→Oct 2026) | -60.0% (Apr 2026→Sep 2026) |
KLRA company outlook (results filed Aug 12, 2026)
- “Data are anticipated in 2028. • Phase 2b high-dose clinical trial in obesity fully enrolled: The Phase 2b trial (NCT07458269) enrolled 264 participants in the U.S. with a BMI of 35 or greater with no type 2 diabetes (T2D).”
- “The trial is expected to enroll approximately 320 adult participants with a BMI of 30 or greater, or a BMI of 27 or greater with at least one co-morbidity, which may include T2D.”
- “The trial initiated in April 2026, with data expected in 2027. • Positive topline data from two Hengrui Pharma Phase 3 trials in obesity/overweight and T2D: In Hengrui's Phase 3 trial in adults with obesity (HARBOR-1, NCT06904105), participants taking HRS-7535 180 mg achieved a mean weight loss of up to 11.1% from baseline at Week 50, based on an ad hoc analysis under the efficacy estimand 3 .”
Quoted word-for-word from the SEC 8-K results press release.
KLRA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-1.01 | $-0.93 | +9.2% | $0 | 5 |
| Next quarter (ends Dec 2026) | $-1.16 | $-1.06 | +9.6% | $0 | 5 |
| Current fiscal year (ends Dec 2026) | $-4.10 | $-3.97 | +3.2% | $0 | 5 |
| Next fiscal year (ends Dec 2027) | $-4.30 | $-4.10 | +4.9% | $0 | 5 |
Key Statistics (as of October 23, 2026 at 09:48 UTC)
| Price | USD 13.27 |
|---|---|
| Change | ▲ 2.71% (up) |
| Previous Close | USD 12.92 |
| Open | USD 12.8 |
| Day Range | USD 12.56 – 13.34 |
| 52-Week Range | USD 9.76 – 28.23 |
| Volume | 855,470 shares |
| Market Cap | $1.72B |
| Exchange | NMS |
Technical Analysis (KLRA)
Nexqual's technical model rates KLRA "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 54.8 (neutral) |
| vs SMA50 | Below (USD 13.89) |
| MACD | -0.3 (negative) |
Analyst Ratings (KLRA)
Wall Street analysts rate KLRA "Buy" based on 6 analysts, with a mean price target of USD 42.4 (range USD 30–57), per Nexqual as of October 23, 2026 at 09:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 42.4 |
| High Target | USD 57 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (KLRA)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -1.01 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.09 vs est -0.73 ▼ miss |
| 2026-03-31 | USD -3.65 vs est -0.55 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financials & Fundamentals (KLRA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.01 |
| Current Ratio | 11.11 |
| Total Cash | $916.74M |
| Total Debt | $10.22M |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financial Health Score (KLRA)
Nexqual rates Kailera Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:48 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $917M cash vs $10M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$222M (TTM) |
| Efficiency | Mixed — No data |
Ownership (KLRA)
| Insider Ownership | +8.91% |
|---|---|
| Institutional Ownership | +90.44% |
| Shares Outstanding | 129.64M |
| Float | 58.48M |
| Short % of Float | +6.70% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Leadership (KLRA)
Kailera Therapeutics, Inc. is led by Ronald C. Renaud Jr., President, CEO & Director, per Nexqual as of October 23, 2026 at 09:48 UTC.
| President, CEO & Director | Ronald C. Renaud Jr. |
|---|---|
| Chief Operating & Business Officer | Paul Douglas Burgess J.D., M.S. |
| Chief Financial Officer | Douglas W. Pagan |
| Vice President of Corporate Communications & Investor Relations | Maura Gavaghan |
Major Backers & Investors (KLRA)
Notable institutional backers of Kailera Therapeutics, Inc. include Bain Capital Investors Llc, RTW Investments LP, Canada Pension Plan Investment Board, according to Nexqual as of October 23, 2026 at 09:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bain Capital Investors Llc | 37.67% |
| RTW Investments LP | 8.31% |
| Canada Pension Plan Investment Board | 5.63% |
| Atlas Venture Life Science Advisors, LLC | 3.99% |
| FMR, LLC | 3.06% |
| Price (T.Rowe) Associates Inc | 2.73% |
| Citadel | 2.5% |
| Adage Capital Partners GP L.L.C. | 2.47% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.26% |
| BlackRock | 3.03% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt